Ampio Pharmaceuticals (AMPE) Competitors $0.0027 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AMPE vs. ARDS, EVLO, CMRA, GNCAQ, GNCA, STAB, PXMD, CLVR, EFTR, and HSTOShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), PaxMedica (PXMD), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Its Competitors Aridis Pharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Statera Biopharma PaxMedica Clever Leaves eFFECTOR Therapeutics Histogen Aridis Pharmaceuticals (NASDAQ:ARDS) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Does the media refer more to ARDS or AMPE? In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score. Company Overall Sentiment Aridis Pharmaceuticals Neutral Ampio Pharmaceuticals Neutral Which has better earnings & valuation, ARDS or AMPE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAridis PharmaceuticalsN/AN/A-$30.37MN/AN/AAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00 Do institutionals and insiders have more ownership in ARDS or AMPE? 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is ARDS or AMPE more profitable? Company Net Margins Return on Equity Return on Assets Aridis PharmaceuticalsN/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A Which has more risk and volatility, ARDS or AMPE? Aridis Pharmaceuticals has a beta of 43.79, indicating that its share price is 4,279% more volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 5.09, indicating that its share price is 409% more volatile than the S&P 500. SummaryAridis Pharmaceuticals beats Ampio Pharmaceuticals on 3 of the 4 factors compared between the two stocks. Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3K$860.33M$5.75B$21.53BDividend YieldN/A4.84%5.73%3.49%P/E Ratio0.001.1775.1829.88Price / SalesN/A119.80457.0651.86Price / CashN/A19.5625.8118.13Price / Book0.006.6613.254.66Net Income-$8.63M-$4.13M$3.29B$999.94M7 Day PerformanceN/A8.33%0.72%0.96%1 Month PerformanceN/A7.85%4.58%4.72%1 Year PerformanceN/A25.87%73.44%16.87% Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020ARDSAridis PharmaceuticalsN/A$0.00-60.0%N/AN/A$11KN/A0.0030Gap DownHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070News CoverageSTABStatera BiopharmaN/A$0.00-50.0%N/AN/A$5KN/A0.0020Gap DownPXMDPaxMedicaN/A$0.00flatN/A-99.9%$2KN/A0.002CLVRClever LeavesN/A$0.00flatN/A+100.0%$1K$17.42M0.00560EFTReFFECTOR Therapeutics0.1237 of 5 stars$0.00flatN/A-99.6%$1KN/A0.0010HSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020 Related Companies and Tools Related Companies Aridis Pharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Statera Biopharma Competitors PaxMedica Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors Histogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMPE Stock Alerts